Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|21|3826-3835

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.21, 2015-11, pp. : 3826-3835

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1695-1701

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patterns of response and progression in patients with BRAF‐mutant melanoma metastatic to the brain who were treated with dabrafenib

By  

CANCER, Vol. 120, Iss. 4, 2014-02 ,pp. : 530-536

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

By  

Oncology, Vol. 93, Iss. 3, 2017-06 ,pp. : 164-176

Karger

Access to resources Recommend Favorite

The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition

By  

CANCER, Vol. 120, Iss. 20, 2014-10 ,pp. : 3142-3153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 7, 2015-06 ,pp. : 875-881

John Wiley & Sons Inc

Access to resources Recommend Favorite